TORONTO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Dundee Corporation (TSX: DC.A) (the "Company” or "Dundee”) announces that further to the news release disseminated on September 26, 2024, it has now received the requisite board approval from TauRX Pharmaceuticals Ltd. ("TauRx”) for the sale of 8,000 shares to a private investor at a price of US$125 per share for proceeds to the Company of US$1,000,000. The transaction has now been completed. Dundee continues to hold 1,007,008 shares of TauRx.

Register to unlock this article

Register to read this story and more for free.

Signing up for an account helps us improve your browsing experience.

Continue

OR

See our subscription options.

Already have an account? Log in here